grepcent public filings, reorganized for comparison

MEDIFAST INC (MED)

CIK: 0000910329. SIC: 2090 Miscellaneous Food Preparations & Kindred Products. Latest 10-K as of: 2026-02-17.

SIC breadcrumb: Manufacturing > Food And Kindred Products > SIC 2090 Miscellaneous Food Preparations & Kindred Products

SEC company page: https://www.sec.gov/edgar/browse/?CIK=910329. Latest filing source: 0001628280-26-008656.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-17 · accession 0001628280-26-008656 · source: SEC companyfacts

Revenue
385,788,000 USD verified
Net income
-18,672,000 USD verified
Assets
247,973,000 USD verified
Free cash flow
1,249,000 USD computed
Net margin
-4.84% computed
Operating margin
-3.68% computed
Revenue YoY
-35.96% computed
ROE
-9.39% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

MED ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 20; per-ratio N printed.MED ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 20; per-ratio N printed.RatioMEDPeer medianPercentileNNet margin-4.8%5.3%1251Operating margin-3.7%7.6%1749Revenue growth-36.0%3.0%051FCF margin0.3%7.6%1650ROE-9.4%9.1%1749ROA-7.5%4.0%1051Liabilities / equity0.251.19449Current ratio4.691.659851

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 20 Food And Kindred Products, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue385,788,000USD20252026-02-17
Net income-18,672,000USD20252026-02-17
Assets247,973,000USD20252026-02-17

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-17. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000910329.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric201420152016201720182019202020212022202320242025
Revenue1,526,087,0001,598,577,0001,072,054,000602,463,000385,788,000
Net income17,835,00027,721,00055,789,00077,916,000102,859,000164,031,000143,568,00099,415,0002,091,000-18,672,000
Operating income26,859,00039,632,00069,063,00091,039,000134,159,000216,241,000184,806,000126,402,0002,878,000-14,213,000
Gross profit205,664,000227,812,000379,899,000536,858,000697,815,0001,127,597,0001,140,414,000775,850,000444,623,000275,187,000
Diluted EPS1.492.294.626.438.6813.8912.739.100.19-1.70
Operating cash flow25,350,00043,237,00060,816,00084,261,000145,196,00094,545,000194,570,000147,657,00024,476,0006,863,000
Capital expenditures2,876,0003,242,0004,940,00010,058,0005,887,00034,209,00016,681,0006,483,0007,454,0005,614,000
Dividends paid11,889,00015,390,00023,160,00035,396,00053,190,00063,856,00071,620,00073,017,000715,000195,000
Share buybacks33,894,00010,516,00029,995,00033,114,0005,000,00055,999,000126,445,0003,602,0000.000.00
Assets121,216,000145,929,000169,429,000194,653,000276,084,000398,326,000316,213,000309,908,000284,213,000247,973,000
Liabilities25,200,00037,348,00060,323,00089,821,000118,838,000195,852,000161,169,000108,427,00074,104,00049,053,000
Stockholders' equity96,016,000106,563,000109,106,000104,832,000157,246,000202,474,000155,044,000201,481,000210,109,000198,920,000
Cash and cash equivalents52,436,00075,077,00081,364,00076,974,000163,723,000104,183,00087,691,00094,440,00090,928,00089,303,000
Free cash flow22,474,00039,995,00055,876,00074,203,000139,309,00060,336,000177,889,000141,174,00017,022,0001,249,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric201420152016201720182019202020212022202320242025
Net margin10.75%8.98%9.27%0.35%-4.84%
Operating margin14.17%11.56%11.79%0.48%-3.68%
Return on equity18.58%26.01%51.13%74.32%65.41%81.01%92.60%49.34%1.00%-9.39%
Return on assets14.71%19.00%32.93%40.03%37.26%41.18%45.40%32.08%0.74%-7.53%
Liabilities / equity0.260.350.550.860.760.971.040.540.350.25
Current ratio4.153.372.411.942.101.811.582.433.344.69

Industry Peer Context

Each number-line places MED against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

MED Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.MED Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.3 SIC peersMin -4.8%Median 0.1%Max 11.5%MED -4.8%

Operating margin peer context

MED Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.MED Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.3 SIC peersMin -3.7%Median 1.4%Max 15.7%MED -3.7%

ROE peer context

MED ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.MED ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.3 SIC peersMin -9.4%Median 0.1%Max 13.8%MED -9.4%

ROA peer context

MED ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.MED ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 2090; peer count 3.3 SIC peersMin -7.5%Median 0.0%Max 6.0%MED -7.5%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

MED FY2025 income statement bridge from reported figures.MED FY2025 income statement bridge from reported figures.MED income bridgeFY2025: revenue to net incomeSource: SEC companyfacts FY2025.Income statement bridgeReported amount-$250.0M$0.0B$500.0M$385.8MRevenue-$110.6MCost$275.2MGross-$289.4MOpEx-$14.2MOperating-$4.5MOther/tax-$18.7MNet income

Figure provenance: SEC companyfacts FY 2025. Revenue: accession 0001628280-26-008656; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001628280-26-008656; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001628280-26-008656; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001628280-26-008656; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

MED FY2025 free cash flow bridge from reported figures.MED FY2025 free cash flow bridge from reported figures.MED free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$125.0M$250.0M$6.9MOperating cash flow-$5.6MCapex$1.2MFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0001628280-26-008656; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001628280-26-008656; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001628280-26-008656; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

MED revenue, last 5 periods. Source: SEC companyfacts FY2025.MED revenue, last 5 periods. Source: SEC companyfacts FY2025.MED RevenueLatest point: FY2025 = $385.8MSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

MED net income, last 5 periods. Source: SEC companyfacts FY2025.MED net income, last 5 periods. Source: SEC companyfacts FY2025.MED Net incomeLatest point: FY2025 = -$18.7MSource: SEC companyfacts FY2025.Fiscal yearNet income-$250.0M$0.0B$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

MED operating income, last 5 periods. Source: SEC companyfacts FY2025.MED operating income, last 5 periods. Source: SEC companyfacts FY2025.MED Operating incomeLatest point: FY2025 = -$14.2MSource: SEC companyfacts FY2025.Fiscal yearOperating income-$250.0M$0.0B$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

MED gross profit, last 5 periods. Source: SEC companyfacts FY2025.MED gross profit, last 5 periods. Source: SEC companyfacts FY2025.MED Gross profitLatest point: FY2025 = $275.2MSource: SEC companyfacts FY2025.Fiscal yearGross profit$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

MED diluted eps, last 5 periods. Source: SEC companyfacts FY2025.MED diluted eps, last 5 periods. Source: SEC companyfacts FY2025.MED Diluted EPSLatest point: FY2025 = -$1.70/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)-$2.00/share$0.00/share$20.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

MED operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.MED operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.MED Operating cash flowLatest point: FY2025 = $6.9MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

MED capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.MED capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.MED Capital expendituresLatest point: FY2025 = $5.6MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

MED dividends paid, last 5 periods. Source: SEC companyfacts FY2025.MED dividends paid, last 5 periods. Source: SEC companyfacts FY2025.MED Dividends paidLatest point: FY2025 = $195.0KSource: SEC companyfacts FY2025.Fiscal yearDividends paid$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: PaymentsOfDividends. Source concepts: us-gaap:PaymentsOfDividends.

MED share buybacks, last 5 periods. Source: SEC companyfacts FY2025.MED share buybacks, last 5 periods. Source: SEC companyfacts FY2025.MED Share buybacksLatest point: FY2025 = $0.0BSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

MED assets, last 5 periods. Source: SEC companyfacts FY2025.MED assets, last 5 periods. Source: SEC companyfacts FY2025.MED AssetsLatest point: FY2025 = $248.0MSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: Assets. Source concepts: us-gaap:Assets.

MED liabilities, last 5 periods. Source: SEC companyfacts FY2025.MED liabilities, last 5 periods. Source: SEC companyfacts FY2025.MED LiabilitiesLatest point: FY2025 = $49.1MSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

MED stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.MED stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.MED Stockholders' equityLatest point: FY2025 = $198.9MSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

MED cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.MED cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.MED Cash and cash equivalentsLatest point: FY2025 = $89.3MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

MED free cash flow, last 5 periods. Source: SEC companyfacts FY2025.MED free cash flow, last 5 periods. Source: SEC companyfacts FY2025.MED Free cash flowLatest point: FY2025 = $1.2MSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001628280-26-008656; filed 2026-02-17. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

1 tracked difference above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

View the filing-by-filing ledger →

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-03. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000910329.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-303.27reported discrete quarter
2023-Q12023-03-313.67reported discrete quarter
2023-Q22023-06-302.77reported discrete quarter
2023-Q32023-06-3030,280,000reported discrete quarter
2023-Q32023-09-30235,869,0002.12reported discrete quarter
2023-Q42023-12-31191,015,0006,035,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-31174,739,0008,316,0000.76reported discrete quarter
2024-Q22024-03-318,316,000reported discrete quarter
2024-Q22024-06-30168,558,000-0.75reported discrete quarter
2024-Q32024-06-30-8,154,000reported discrete quarter
2024-Q32024-09-30140,163,0000.10reported discrete quarter
2024-Q42024-12-31119,003,000801,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-31115,728,000-772,000-0.07reported discrete quarter
2025-Q22025-03-31-772,000reported discrete quarter
2025-Q22025-06-30105,555,0000.22reported discrete quarter
2025-Q32025-06-302,480,000reported discrete quarter
2025-Q32025-09-3089,409,000-0.21reported discrete quarter
2025-Q42025-12-3175,096,000-18,119,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-3176,044,000-2,122,000-0.19reported discrete quarter
2026-Q22026-03-31-2,122,000reported discrete quarter
2026-Q22026-06-3076,384,000-0.28reported discrete quarter

Quarterly Charts

MED quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.MED quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.MED Quarterly RevenueLatest point: 2026-Q2 = $76.4MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$125.0M$250.0M2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001628280-26-051928; filed 2026-08-03. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

MED quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.MED quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.MED Quarterly Net incomeLatest point: 2026-Q2 = -$2.1MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-03-31; accession 0001628280-26-029898; filed 2026-05-04. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

MED quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.MED quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.MED Quarterly Diluted EPSLatest point: 2026-Q2 = -$0.28/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$1.00/share$0.00/share$6.00/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001628280-26-051928; filed 2026-08-03. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read MED's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read MED's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001628280-26-051928.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-03. Report date: 2026-06-30.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). Forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” “anticipate,” “expect,” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management of Medifast and are subject to certain events, risks, uncertainties, and other factors. These risks and uncertainties include, but are not limited to, those described in our 2025 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report. We undertake no obligation to update any information contained in this report or to publicly release the results of any revisions to forward-looking statements to reflect events or circumstances of which we may become aware after the date of this report.

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

Overview

Medifast, Inc. (“Medifast,” the “Company,” “we” or “us”) is the health and wellness company known for its science-backed, comprehensive metabolic health system. In October 2025, Medifast announced its strategic transformation, unveiling its focus on holistic metabolic health. The Company started 2026 by moving from transformation to execution, leveraging its extensive experience in structured weight loss coupled with recent scientific research and enhanced product offerings to address the needs of a broader metabolic health market. In July 2026, Medifast announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The transition from OPTAVIA® to a new brand with the launch of Trilivy represents an evolution of the company’s vision, platform, and purpose, expanding beyond traditional weight

16

Table of Contents

loss to address the broader metabolic health challenges impacting more than 90% of U.S. adults today. Medifast’s approach focuses on addressing the root cause of metabolic dysfunction. This strategic shift targets a larger and what is believed to be a more sustainable market, focusing on a long-term growth strategy intended to guide the Company over the next decade by aligning science, products, and coaching with increasing demand for new solutions as awareness of metabolic dysfunction grows.

This growth strategy will initially be focused on improving coach productivity and expanding our coach network. We operate a well-capitalized business with a powerful lifestyle solution and a business model that has impacted over 3 million lives and, for the quarter ended June 30, 2026, had a network of approximately 11,700 active earning independent coaches. Medifast stands at the forefront of evidence-based wellness solutions, and its coach-first model creates significant opportunities for coaches’ individual businesses. This is designed to create a “flywheel effect” as new clients join, driving coach productivity, which in turn attracts new active earning coaches, leading to even more new clients and further productivity.

The Company offers a simple, yet comprehensive approach to achieving optimal metabolic health and well-being by empowering individuals to make lasting changes. Through the dedicated support of our coaches, approximately 90% of whom were clients first, our clients are guided through every step of their wellness journey.

Our scientifically developed products and habit creation framework, reinforced by coaches and community support, provide proven health benefits and serve as a promising foundation to develop a comprehensive metabolic health system. We continuously innovate and build upon our scientific and clinical heritage to fulfill our mission of lifelong transformation, through metabolic science and human connectionTM. Coaches provide unparalleled support along with community, nutrition, and healthy habits. In a world where health and well-being can often be a difficult and solitary journey, our comprehensive system offers intensely personalized support to individuals seeking to transform their health. The goal of this holistic approach is to empower people to master their metabolic health and improve body composition, beginning with a quality weight loss journey and offering the flexibility to achieve it on their own terms. At the heart of the metabolic health system is a powerful three-part delivery model that helps individuals build healthier habits, unlock their potential and achieve optimal metabolic health:

Independent Coaches & Community: Coaches provide individualized support and guidance to clients on their path to optimal metabolic health and well-being and a community of like-minded individuals offer real-time connection and support.

The Habits of Health Transformational System: A proprietary system that provides easy steps toward a sustainable healthy lifestyle.

Science & Products: Clinically proven plans and scientifically developed products, backed by dietitians, scientists, and physicians.

In October 2025, the Company introduced Metabolic Synchronization® — a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. Research demonstrates that the Company's comprehensive system improves metabolic health by activating strong and targeted fat burn (i.e., by reducing bad visceral fat), preserving lean mass, and protecting muscle.1 This approach results in healthy, quality weight loss that extends beyond the scale, ultimately empowering individuals to achieve their health goals.

Metabolic health, often misunderstood or overlooked, refers to the body’s ability to efficiently convert food into energy and regulate critical bodily functions. Metabolic dysfunction is a state that can often go unnoticed, placing strain on the body’s metabolic processes and potentially leading to serious health challenges.

Science has always been integral to Medifast’s identity. Through ongoing research and compelling data that elevate the science behind the Company’s plans and innovative products, the Company is energizing its coach community to empower individuals to take control of their metabolic health. In July 2026, the company introduced the Trilivy Reset Fueling line, enhanced with MetaVantage Technology™, which further supports metabolic health by helping reduce waist circumference while also supporting normal fat metabolism and healthy insulin function.2 We expect to bring the updated product line fully to market this quarter. These upcoming innovations are expected to further strengthen the Company’s offerings to help clients achieve optimal metabolic health.

1 In a clinical study, individuals on the Company's 5 & 1 Plan experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Arterburn, L.M., C.D. Coleman, J. Kiel, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract 2019; 5/1: 3-14.

2 Pedret, A., R.M. Valls, L. Calderon-Perez, et al. Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. Int J Obes (Lond). 2019;43(9):1863- 1868. doi: 10.1038/s41366-018-0220-0.

17

Table of Contents

While GLP-1 medication usage continues to accelerate, medication alone may not be adequate for achieving sustainable, long-term health outcomes without the integration of comprehensive lifestyle modifications, nutritional guidance, and behavioral support. Recent research indicates that approximately one-third of users discontinue the medication after six months, and up to 74% stop after a year.3 Furthermore, studies show that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment, with cardiometabolic benefits often reversing as well.4 GLP-1 medications can be effective tools, but lasting results require more than just medication—they demand holistic behavior change.

The need for change extends beyond the obesity epidemic, as over 90% of Americans are metabolically unhealthy,5 impacting biomarkers of poor health, energy regulation, and weight management. Healthy, quality weight loss that prioritizes burning fat while preserving muscle is essential for improving metabolic health but it demands commitment, consistency, and support. Given that GLP-1 medications are shown to be most effective when combined with lifestyle changes, we see strong alignment with our expertise in helping people create durable habits through coach-supported, behavior-based systems. Our experience in guiding individuals towards change through habit-based systems, supported by a coach, is highly compatible with the demonstrated effectiveness of these medications when paired with lifestyle modifications.

In addition to coach support, by focusing on the root causes of metabolic dysfunction, Medifast is seeking to unlock new opportunities to reach and empower individuals at every stage of their health journey. For those utilizing weight loss medications, Medifast’s programs are intended to provide complementary solutions to enhance metabolic function and overall health.

Regardless of their need states, our integrated, coach-supported, lifestyle-based approach helps clients achieve their health goals. Coaches introduce clients to a set of healthy habits, often beginning with healthy eating, alongside exclusive products and plans. These offerings are a key component that supports the Company’s mission and helps clients to build and sustain healthy habits in their lives.

Finding new clients and reactivating former clients remains an important area of focus for our business and our coaches. We believe our coach-based model is scalable, drives both client success and growth, and represents a key competitive advantage. The coaching model is anchored on clients’ needs, helping place them into supportive and energized health and wellness communities that share similar challenges and goals. With a coach, clients successfully lost 10 times more weight and 17 times more fat than those attempting to lose weight on their own.6 Coaches deliver highly tailored and personalized support and motivation, sharing their passion for healthy living and lifestyle transformation. Despite their diverse geographies and backgrounds, our coaches form a tight-knit community that supports, encourages, and inspires one another.

Our coaches are independent contractors, not employees, who support clients and market our products and services to friends, family, and other people in their communities, primarily through word-of-mouth, email, and social media channels including Facebook, Instagram, X (formerly known as Twitter), and video conferencing platforms. Products are shipped directly to clients; coaches do not handle or deliver products. This model enables our coaches to focus on client support

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001628280-26-008656. The complete FY 2025 MD&A is published at /company/MED/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-02-17. Report date: 2025-12-31.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. Our significant accounting policies are described in Note 2 to the consolidated financial statements.

The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Management considers the following accounting policies to be the most critical in preparing our consolidated financial statements. These critical accounting policies have been discussed with our Audit Committee, as appropriate.

Revenue Recognition: Our revenue is derived primarily from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other healthy living products. Revenue is recognized upon delivery to the shipping carrier and net of discounts, rebates, promotional adjustments, price adjustments, allocated consideration to loyalty programs, and estimated returns.

Our performance obligations are satisfied at a point in time. Revenue from products transferred to customers at a point in time accounted for substantially all of our revenue for the years ended December 31, 2025, 2024, and 2023.

Our return policy allows for customer returns of consumable products from the time of order until 30 days following the date of receipt, and upon our authorization. We adjust revenues for the products expected to be returned and a liability is recognized for expected refunds to customers. We estimate expected returns based on historical levels and project this experience into the future.

Our sales contracts may give customers the option to purchase additional products priced at a discount. Options to acquire additional products at a discount can come in many forms, such as customer reward programs and incentive offerings including pricing arrangements, and promotions.

We reduce the transaction price for customer reward programs and certain incentive offerings including pricing arrangements, promotions, and incentives that represent variable consideration and separate performance obligations. The Company allocates consideration between the initial sale of products and the customer reward program and incentive offering. The Company discontinued its reward program in July 2025.

Amounts billed to customers for shipping and handling activities are treated as a promised service performance obligation and are recorded as revenue in our Consolidated Statements of Operations upon fulfillment of the performance obligation. Shipping and handling costs incurred by the Company for the delivery of products to customers are considered a cost to fulfill the contract and are included in cost of sales in our Consolidated Statements of Operations.

We expense coach compensation and credit card fees during the period in which the corresponding revenue is earned. These costs are recorded in selling, general and administrative expense in our Consolidated Statements of Operations.

Long-lived Asset Impairment: Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Income Taxes: Deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

33

Table of Contents

The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in our Consolidated Balance Sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

Our policy is to recognize interest and penalties accrued on uncertain tax positions as part of income tax expense.

BACKGROUND

Medifast (NYSE: MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to help address the challenges of metabolic dysfunction, the Company’s holistic approach integrates personalized plans, scientifically developed products and a framework for habit creation — all supported by a dedicated network of independent coaches. Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization™, a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body’s metabolism. Research shows the Company’s comprehensive system activates strong and targeted fat burn to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle. Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making Healthy Lifestyle Second Nature. Our product sales accounted for approximately 96.4%, 96.8% and 97.5% of our revenues in each of 2025, 2024, and 2023, respectively. We review and analyze a number of key operating and financial metrics to manage our business, including the number of active earning coaches and average quarterly revenue generated per active earning coach. The number of active earning coaches decreased by approximately 40.6% to 16,100 for the quarter ended December 31, 2025 from the quarter ended December 31, 2024, and the average revenue per active earning coach was increased 6.2% to $4,664 for the quarter ended December 31, 2025 from the quarter ended December 31, 2024.

Our OPTAVIA business unit accounted for all of our revenues for each the years ended 2025, 2024 and 2023. We have operated and reported as a single sales segment, OPTAVIA, since 2018. By maintaining our commitment to building capabilities in the areas that matter most to our coaches and clients within the OPTAVIA channel, we believe our strong financial foundation, flexible model and variable cost structure coupled with disciplined growth initiatives position Medifast for the current environment and the future.

34

Table of Contents

CONSOLIDATED RESULTS OF OPERATIONS - 2025 COMPARED TO 2024

The following table reflects our Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 (in thousands, except percentages):

20252024$ Change% Change
Revenue$385,788$602,463$(216,675)(36.0)%
Cost of sales110,601157,840(47,239)(29.9)%
Gross profit275,187444,623(169,436)(38.1)%
Selling, general, and administrative289,400441,745(152,345)(34.5)%
Income (loss) from operations(14,213)2,878(17,091)(593.8)%
Other income
Interest income5,5164,80471214.8%
Other income (expense)3,058(3,895)6,953178.5%
8,5749097,665843.2%
Income (loss) before provision for income taxes(5,639)3,787(9,426)(248.9)%
Provision for income taxes13,0331,69611,337668.5%
Net income (loss)$(18,672)$2,091$(20,763)(993.0)%
% of revenue
Gross profit71.3%73.8%
Selling, general, and administrative75.0%73.3%
Income (loss) from operations(3.7)%0.5%

Revenue: Revenue decreased $216.7 million, or 36.0%, to $385.8 million in 2025 from $602.5 million in 2024. The year-over-year decline in revenue was primarily driven by a decrease in the number of active earning coaches. The total number of active earning coaches for the three months ended December 31, 2025 decreased to 16,100 from 27,100 for the corresponding period in 2024, a decrease of 40.6%. The number of active earning coaches has been trending downward year-over-year since the first quarter of 2023. The decrease in the number of active earning coaches was driven by continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss. The average revenue per active earning coach increased 6.2% to $4,664 for the three months ended December 31, 2025 from $4,391 for the three months ended December 31, 2024. The increase in the revenue per active earning coach for the quarter was driven by greater alignment of our network of coaches, prioritizing productive coaches and efficient coach network structures.

Costs of sales: Cost of sales decreased $47.2 million, or 29.9%, to $110.6 million in 2025 from $157.8 million in 2024. The decrease in cost of sales was primarily driven by an approximately $54.9 million decrease due to lower sales volumes and a $2.6 million decrease due to restructuring of external manufacturing agreements that did not recur in 2025, partially offset by $8.0 million of loss of leverage on fixed costs and $3.0 million of inventory reserves which are primarily related to the reformulation of the Essential product line.

Gross profit: In 2025, gross profit decreased $169.4 million, or 38.1%, to $275.2 million from $444.6 million in 2024. The decrease in gross profit was primarily attributable to lower revenue. As a percentage of sales, gross profit decreased 250 basis points to 71.3% for 2025 from 73.8% for 2024 primarily driven by the loss of leverage on fixed costs.

Selling, general and administrative: Selling, general and administrative (“SG&A”) expenses were $289.4 million in 2025, a decrease of $152.3 million, or 34.5%, as compared to $441.7 million in 2024, primarily due to a $85.1 million decrease in

35

Table of Contents

coach compensation due to lower sales volumes and a decrease in the number of active earning coaches, a $13.4 million decrease in company-led marketing related expenses, a $12.5 million decrease for supply chain optimization that did not

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for MED

Indicators mapped to this company's SIC classification (industry 2090 Miscellaneous Food Preparations & Kindred Products) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Inflation (CPI / PCE / PPI), US labor market, Growth & output, Money & trade, Government finances, Sector employment, Industrial orders & inventories, Trade & external.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/MED.md · JSON record: /company/MED.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt